# Bio-Thera Solutions clinical trials: 57 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 57 trials with Bio-Thera Solutions as lead sponsor, 4 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Bio-Thera Solutions: 57 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/bio-thera-solutions

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 57
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 57, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 7, 2026 | NCT07515079 | Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | Bio-Thera Solutions | Phase 3 | Recruiting | Diabetic Macular Edema (DME) | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07515079) |
| March 30, 2026 | NCT07499700 | A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis | Bio-Thera Solutions | Phase 2/3 | Recruiting | Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS) | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07499700) |
| September 18, 2025 | NCT07180862 | A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants | Bio-Thera Solutions | Phase 1 | Active not recruiting | Carcinoma, Non-Small-Cell Lung | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07180862) |
| August 9, 2024 | NCT06545617 | A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer | Bio-Thera Solutions | Phase 1/2 | Withdrawn | Platinum-resistant Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06545617) |
| April 19, 2024 | NCT06376136 | A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection... | Bio-Thera Solutions | Phase 1/2 | Active not recruiting | Advanced Solid Tumors | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06376136) |
| April 2, 2024 | NCT06341114 | A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of... | Bio-Thera Solutions | Phase 1/2 | Active not recruiting | Advanced Solid Tumors | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06341114) |
| March 20, 2024 | NCT06321068 | BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial... | Bio-Thera Solutions | Phase 2/3 | Terminated | Endometrial Cancer | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06321068) |
| February 28, 2024 | NCT06280196 | A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC | Bio-Thera Solutions | Phase 3 | Terminated | Carcinoma, Non-Small-Cell Lung | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06280196) |
| November 18, 2023 | NCT06139536 | Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients | Bio-Thera Solutions | Phase 1 | Completed | Advanced Solid Tumor | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06139536) |
| November 9, 2023 | NCT06123884 | BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | Bio-Thera Solutions | Phase 2/3 | Recruiting | Cervical Cancer | 526 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06123884) |
| November 1, 2023 | NCT06111196 | Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects | Bio-Thera Solutions | Phase 1 | Completed | Healthy Male Subjects | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06111196) |
| October 23, 2023 | NCT06094179 | Evaluate the Safety, Tolerability of BAT6026 | Bio-Thera Solutions | Phase 1/2 | Active not recruiting | Dermatitis, Atopic | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06094179) |
| September 21, 2023 | NCT06044350 | A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders | Bio-Thera Solutions | Phase 2 | Active not recruiting | Optic Neuromyelitis Spectrum Disease | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06044350) |
| August 1, 2023 | NCT05968508 | A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled... | Bio-Thera Solutions | Phase 1 | Completed | Healthy Men | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05968508) |
| May 30, 2023 | NCT05879627 | To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors | Bio-Thera Solutions | Phase 1 | Terminated | Advanced Solid Tumors | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05879627) |
| May 19, 2023 | NCT05865574 | A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection | Bio-Thera Solutions | Phase 1 | Completed | Healthy Men | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05865574) |
| May 8, 2023 | NCT05848466 | Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients | Bio-Thera Solutions | Phase 1 | Completed | Advanced or Metastatic Solid Tumors | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05848466) |
| April 7, 2023 | NCT05803187 | Clinical Study of Stage IV Psoriasis in Children With Geleli | Bio-Thera Solutions | Observational | Completed | Plaque Psoriasis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05803187) |
| March 14, 2023 | NCT05767060 | BAT7104 Injection in Patients With Advanced Malignant Tumors. | Bio-Thera Solutions | Phase 1 | Completed | Advanced Malignant Tumor | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05767060) |
| November 17, 2022 | NCT05620017 | Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection | Bio-Thera Solutions | Phase 1 | Recruiting | Advanced Solid Tumors | 182 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05620017) |
| October 12, 2022 | NCT05576454 | Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects | Bio-Thera Solutions | Phase 1 | Completed | Severe Asthma | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05576454) |
| August 29, 2022 | NCT05518695 | Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese Subjects | Bio-Thera Solutions | Phase 1 | Completed | SARS-CoV-2 Infection | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05518695) |
| June 30, 2022 | NCT05439629 | Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration | Bio-Thera Solutions | Phase 3 | Completed | Neovascular (Wet) Age-related Macular Degeneration | 488 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05439629) |
| June 10, 2022 | NCT05414136 | Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 | Bio-Thera Solutions | Phase 1 | Completed | Advanced Solid Tumor | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05414136) |
| June 6, 2022 | NCT05405621 | Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009 | Bio-Thera Solutions | Phase 1 | Unknown | Locally Advanced/Metastatic Solid Tumours | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05405621) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 33 |
| Phase 1/2 | 7 |
| Phase 2 | 2 |
| Phase 2/3 | 3 |
| Phase 3 | 10 |
| Phase 4 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Terminated | 7 |
| Active not recruiting | 5 |
| Unknown | 4 |
| Recruiting | 4 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Arthritis, Psoriatic | 3 |
| Psoriasis | 2 |
| Macular Degeneration | 2 |
| Arthritis, Rheumatoid | 2 |
| COVID-19 | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Endometrial Neoplasms | 1 |
| Fallopian Tube Neoplasms | 1 |
| Spondylitis, Ankylosing | 1 |
| Dermatitis, Atopic | 1 |
| Uterine Cervical Neoplasms | 1 |
| Nephrosis, Lipoid | 1 |
| Glomerulosclerosis, Focal Segmental | 1 |
| Neuromyelitis Optica | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Melanoma | 1 |
| Uveitis | 1 |
| Asthma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Theme restaurants in the United States](https://specstream.ai/data/businesses/theme-restaurants/united-states)
- [Child psychiatry practices in the United States](https://specstream.ai/data/businesses/child-psychiatry-practices/united-states)
- [Infectious disease clinics in the United States](https://specstream.ai/data/businesses/infectious-disease-clinics/united-states)
- [Rubber and plastics manufacturers in the United States](https://specstream.ai/data/businesses/rubber-and-plastics-manufacturers/united-states)
- [B2B secretarial companies in the United States](https://specstream.ai/data/businesses/b2b-secretarial-companies/united-states)
- [Forestry services in the United States](https://specstream.ai/data/businesses/forestry-services/united-states)
